

The Depository Trust Company

IMPORTANT

B#: 3696

DATE: July 29, 2002

TO: All Participants

CATEGORY: Dividends

FROM: Nilesh Desai, Supervisor, Dividend Department

ATTENTION: Dividend Managers, Cashiers & Reorganization Managers

SUBJECT: Rights: Tutogen Medical, Inc.
Common CUSIP#: 901107102
R/D: 7/31/2002 Expires: 7/30/2012
Rate: 1 preferred share purchase right for each share held


The Board of Directors of Tutogen Medical, Inc. (the "Company") has declared a dividend distribution of one Preferred Share Purchase Right (a "Right") for each share of common stock held as of the record date.

No physical rights will be issued at this time.

On July 31, 2002, you automatically will own one preferred purchase right for each share of common stock you own. These rights will expire on July 30, 2012, unless the Company redeems them before that time or they become exercisable.

For more information see the attached Bloomberg Notice.

If participants have any questions concerning this Important Notice, please contact Mr. John Pastorino or Mr. Ray Lew of DTC's Stock Dividend Department at (212) 855-4517/4523.


INTERNATIONAL
SITESGo to...

STOCK QUOTES

Enter symbol:
Lookup symbol
 MONITOR

 HOME

 MARKETS

 MONEY

 LIFE

 TV

 RADIO

 CHARTS

 TOOLS

 HELP

 BLOOMBERG L.P.

NEWS

Top Financial News
 Top World News
 Stock Market Update
 After Hours Trading
 Earnings News
 Profit Warnings
 Technology
 Analyst Ratings
 Politics
 Economies
 Fed Watch
 Columns
 News Archive

STOCKS

Earnings Center
 Tech Stocks
 Stocks on the Move
 Chart Builder
 World Indices
 Movers by Exchange
 Stocks in the Dow
 S&P 500 Snapshot
 Industry Movers
 Most Active Options
 IPO Center
 Regional Indices

RATES & BONDS

Key Rates
 U.S. Treasuries
 Government Bonds
 Municipal Bonds

CURRENCIES

Currency Rates
 Cross Currency Rates
 Currency Calculator
 EMU Update

COMMODITIES

Most Active Futures
 Commodity Movers
 Energy

Tutogen Medical, Inc. Adopts Shareholder Rights Plan

Business/Medical Editors

CLIFTON, N.J.--(BUSINESS WIRE)--July 17, 2002--(AMEX:TTG) The Board of Directors of Tutogen Medical, Inc. declared a dividend distribution of one Preferred Share Purchase Right for each outstanding share of its common stock to shareholders of record on July 31, 2002.

The Company stated that the rights, which expire on July 30, 2012, are designed to assure that all of Tutogen's shareholders receive fair and equal treatment in the event of any proposed takeover of the Company and to guard against abusive tactics to gain control of the Company without paying all shareholders a premium for that control. The rights being adopted are in response to the general takeover environment and are intended to enable all Tutogen shareholders to realize the long-term value of their investment in the Company. Each right will entitle its holder to purchase, at the right's then current exercise price, a number of Tutogen's common shares having a market value of twice such price. The rights should encourage anyone seeking to acquire the Company to negotiate in good faith with its Board of Directors.

Tutogen Medical, Inc. is engaged in the processing, distribution and development of biological implant products made from human (allograft) and animal (xenograft). Tutogen utilizes its patented Tutoplast(R) process of tissue preservation and viral inactivation, to manufacture bioimplants used across multiple medical market segments including spinal/trauma, urology, dental, ophthalmology, and general surgery. The Company's Tutoplast(R) products are sold and distributed worldwide by Centerpulse, formerly Sulzer Medica (NYS: CEP), the Mentor Corporation (NMS: MNTR), IOP, Inc. and through subsidiaries in the U.S. and Germany. For more information, visit the Company's web site at <http://www.tutogen.com>.

Certain statements in this news release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may differ materially from those set forth in these statements. In addition, the economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission could affect such result.

--30--mw/ny*

CONTACT: Tutogen Medical, Inc., Clifton

George Lombardi, 973/365-2799

glombardi@tutogen.com

or

Michael Brod Associates

Michael Brod, 917/576-1043

mb@michaelbrod.com

KEYWORD: NEW JERSEY

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES
PHARMACEUTICAL

SOURCE: Tutogen Medical, Inc.

Today's News On The Net - Business Wire's full file on the Internet

with Hyperlinks to your home page.

URL: <http://www.businesswire.com>

-0- Jul/17/2002 19:14 GMT